Sarepta Therapeutics (SRPT) Change in Accured Expenses (2010 - 2026)

Sarepta Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 138.36% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at $91.8 million (down 56.77% YoY), while the FY2025 annual figure was $104.3 million, down 5.77% from the prior year.
• Change in Accured Expenses was -$3.4 million for Q1 2026 at Sarepta Therapeutics, down from $249.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $249.6 million in Q4 2025 to a low of -$103.2 million in Q3 2025.
• Historically, Change in Accured Expenses has averaged $18.2 million across 5 years, with a median of $1.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses soared 396.97% in 2024, then tumbled 6223.03% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $12.9 million in 2022, then jumped by 374.36% to $61.1 million in 2023, then jumped by 103.34% to $124.2 million in 2024, then surged by 100.96% to $249.6 million in 2025, then plunged by 101.38% to -$3.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.4 million (Q1 2026), $249.6 million (Q4 2025), and -$103.2 million (Q3 2025), per Business Quant data.